探索三替代腺因衍生物作为具有对抗活性的腺素A1受体配体:合成,生物评估和分子建模
Laura B Córdoba-Gómez1, Álvaro Lorente-Macías2, María Isabel Loza3
1Departamento Química Farmacéutica y Orgánica, Facultad de Farmacia, Universidad de Granada, Spain.
Bioorganic chemistry
|March 28, 2025
概括
研究人员开发了针对腺受体 (ARs) 的新型腺类似物. 最强效的化合物选择性地对抗了 hA1AR,并显示出对癌细胞的显著抗增殖活性,支持AR药物开发.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 癌症研究 癌症研究
背景情况:
- 氨酸受体 (AR) 配体由于其生理病理学作用,显示出治疗潜力.
- 了解AR功能对于开发新疗法至关重要.
研究的目的:
- 合成和生物选新型三替代腺素类似物.
- 评估AR结合亲和力和抗增殖活性.
- 为潜在的治疗应用发现有选择性的AR配体.
主要方法:
- 通过循环化合成了六种新型的三替代腺因类似物.
- 评估AR结合亲和力和选择性,特别是对于人类腺A1受体 (hA1AR).
- 确定了对六种癌细胞系的抗增殖活性,并进行了对接研究.
主要成果:
- 鉴定出具有选择性结合亲和力对 hA1AR.ar 的衍生物.
- 最强效的化合物N6,9-diisopropyl-8-phenyl-9H-purin-6-amine (14c) 的Ki值为2nM,显示出Ki值为2nM,而N6,9-diisopropyl-8-phenyl-9H-purin-6-amine (14c) 的Ki值为2nM.
- N6,9-dicyclopentyl-8-phenyl-9H-purin-6-amine (19c) 显示出强大的抗增殖活性,其微分子EC值低<50>.
结论:
- 新型腺因衍生物对H1AR有选择性的对抗性活性.
- 化合物19c是癌症研究的有希望的候选物,因为它具有强大的抗增殖作用.
- 对于AR药物开发,需要进一步探索氨酸支架.
相关概念视频
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...
Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...


